Skip to main content
4BASEBIO PLC logo

4BASEBIO PLC — Investor Relations & Filings

Ticker · 4BB ISIN · GB00BMCLYF79 LEI · 213800E2DX9EAIUNCB30 IL Manufacturing
Open in API
Filings indexed 92 across all filing types
Latest filing 2023-02-09 Share Issue/Capital Cha…
Country GB United Kingdom
Listing IL 4BB

About 4BASEBIO PLC

https://www.4basebio.com/

4BASEBIO PLC is a biotechnology company specializing in the design and manufacturing of synthetic DNA for next-generation therapeutics and vaccines. The company provides high-purity, Good Manufacturing Practice (GMP) grade nucleic acid products, including its proprietary opDNA®, as a plasmid-free alternative to traditional methods. Its technology is engineered to accelerate development timelines, enhance safety, and improve manufacturing scalability for applications in genetic medicine, including mRNA vaccines, viral vector-based gene therapies, and gene editing. 4basebio's solutions aim to eliminate production bottlenecks and de-risk manufacturing for partners in the pharmaceutical and biotechnology sectors.

Recent filings

Filing Released Lang Actions
4basebio Plc - Exercise of Options and Issue of Equity
Share Issue/Capital Change Classification · 1% confidence The document announces the 'Exercise of Options and Issue of Equity' resulting in new ordinary shares being admitted to trading on AIM. It details the number of shares issued, the total voting rights, and mentions the Financial Conduct Authority's Disclosure and Transparency Rules. This activity directly relates to changes in the company's share capital structure and issuance of new shares, which aligns precisely with the definition of 'Share Issue/Capital Change' (SHA). It is not a general financing update (CAP) as it is a specific transaction involving employee options, nor is it a director's dealing (DIRS) or a general regulatory filing (RNS).
2023-02-09 English
4basebio Plc - Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is a 'TR-1: Standard form for notification of major holdings' filed with the National Storage Mechanism. This form is used to report changes in significant share ownership (crossing thresholds) by individuals or entities. This specific filing details an acquisition of voting rights by DELPHI Unternehmensberatung Aktiengesellschaft, crossing the notification threshold. This type of filing, which reports insider or major shareholder transactions/holdings, corresponds directly to the 'Director's Dealing' or 'Major Shareholding Notification' categories. Since the document explicitly details the resulting situation of voting rights held by a major shareholder, it fits the definition of Major Shareholding Notification (MRQ) better than DIRS (which is typically for directors' personal trades, though there is overlap in intent). However, looking at the provided definitions, 'Director's Dealing' (DIRS) is for personal share transactions by directors/executives, and 'Major Shareholding Notification' (MRQ) is for changes in significant share ownership levels (crossing thresholds). Since this is a notification of crossing a major holding threshold (22.006560% held), MRQ is the most precise fit among the options, although DIRS is also closely related to insider reporting. Given the structure and purpose (reporting a major holding crossing a threshold), MRQ is selected.
2023-02-09 English
4basebio Plc - Half-year Report
Interim / Quarterly Report Classification · 1% confidence The document is a 'Half-year Report' for 4basebio PLC for the period ended 30 June 2022. It contains comprehensive financial statements, including a consolidated statement of profit or loss, balance sheet data, and management commentary (Chairman's Statement). Since it covers a period shorter than a full fiscal year and includes substantive financial data, it is classified as an Interim/Quarterly Report (IR). H1 2022
2022-09-30 English
Second Price Monitoring Extn
Regulatory Filings Classification · 1% confidence The document is very short (1931 characters) and contains the header 'RNS Number : 8192A'. It announces a 'Second Price Monitoring Extension' related to trading activity, which is a specific operational announcement. Since it is a short, specific regulatory update that doesn't fit into the defined categories like ER, IR, or 10-K, and it is distributed via RNS (the news service of the London Stock Exchange), it best fits the general regulatory announcement category, RNS, which serves as a fallback for miscellaneous regulatory filings.
2022-09-27 English
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document is very short (1914 characters) and announces a 'Price Monitoring Extension' for a security on the London Stock Exchange, referencing the 'RNS Number' and stating that RNS is the news service approved by the Financial Conduct Authority (FCA). This is a general regulatory announcement concerning trading mechanics, not a specific financial report (like 10-K, IR, or ER). Since it is a general regulatory announcement that doesn't fit the specific categories like DIRS, DIV, or DLST, the most appropriate fallback category is Regulatory Filings (RNS).
2022-09-27 English
4basebio Plc - Director/PDMR Shareholding
Director's Dealing Classification · 1% confidence The document explicitly announces a 'Director/PDMR Shareholding' and details a 'Transfer' of shares by the Chief Executive Officer (Dr Heikki Lanckriet). It includes a formal notification structure pursuant to Article 19(1) of Regulation (EU) No. 596/2014, which governs insider transactions. This directly corresponds to the definition of Director's Dealing (DIRS). The document is a notification of a transaction by an insider, not a general regulatory filing (RNS) or a report about remuneration (DEF 14A).
2022-07-13 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.